vs
Side-by-side financial comparison of Hologic (HOLX) and RXO, Inc. (RXO). Click either name above to swap in a different company.
RXO, Inc. is the larger business by last-quarter revenue ($1.5B vs $1.0B, roughly 1.4× Hologic). Hologic runs the higher net margin — 17.1% vs -3.1%, a 20.2% gap on every dollar of revenue. On growth, Hologic posted the faster year-over-year revenue change (2.5% vs -11.9%). Hologic produced more free cash flow last quarter ($215.2M vs $-9.0M). Over the past eight quarters, RXO, Inc.'s revenue compounded faster (26.8% CAGR vs 1.5%).
Hologic, Inc. is an American medical technology company primarily focused on women's health; it sells medical devices for diagnostics, surgery, and medical imaging.
RXO, Inc. is a leading transportation and logistics solutions provider headquartered in the United States. Its core service portfolio includes freight brokerage, last-mile delivery for heavy and bulky goods, managed transportation services, and end-to-end supply chain optimization support, primarily catering to clients across the North American manufacturing, retail, and e-commerce segments.
HOLX vs RXO — Head-to-Head
Income Statement — Q1 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $1.0B | $1.5B |
| Net Profit | $179.1M | $-46.0M |
| Gross Margin | 56.0% | — |
| Operating Margin | 22.6% | -2.9% |
| Net Margin | 17.1% | -3.1% |
| Revenue YoY | 2.5% | -11.9% |
| Net Profit YoY | -10.9% | -84.0% |
| EPS (diluted) | $0.79 | $-0.28 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $1.0B | $1.5B | ||
| Q3 25 | $1.0B | $1.4B | ||
| Q2 25 | $1.0B | $1.4B | ||
| Q1 25 | $1.0B | $1.4B | ||
| Q4 24 | $1.0B | $1.7B | ||
| Q3 24 | $988.0M | $1.0B | ||
| Q2 24 | $1.0B | $930.0M | ||
| Q1 24 | $1.0B | $913.0M |
| Q4 25 | $179.1M | $-46.0M | ||
| Q3 25 | $187.2M | $-14.0M | ||
| Q2 25 | $194.9M | $-9.0M | ||
| Q1 25 | $-17.4M | $-31.0M | ||
| Q4 24 | $201.0M | $-25.0M | ||
| Q3 24 | $178.6M | $-243.0M | ||
| Q2 24 | $194.5M | $-7.0M | ||
| Q1 24 | $169.9M | $-15.0M |
| Q4 25 | 56.0% | — | ||
| Q3 25 | 55.6% | — | ||
| Q2 25 | 56.3% | — | ||
| Q1 25 | 37.5% | — | ||
| Q4 24 | 56.8% | — | ||
| Q3 24 | 56.4% | — | ||
| Q2 24 | 55.4% | — | ||
| Q1 24 | 53.3% | — |
| Q4 25 | 22.6% | -2.9% | ||
| Q3 25 | 22.6% | -0.5% | ||
| Q2 25 | 24.9% | — | ||
| Q1 25 | -0.7% | -2.1% | ||
| Q4 24 | 22.5% | -1.4% | ||
| Q3 24 | 23.3% | -1.9% | ||
| Q2 24 | 24.1% | — | ||
| Q1 24 | 20.7% | -1.3% |
| Q4 25 | 17.1% | -3.1% | ||
| Q3 25 | 17.8% | -1.0% | ||
| Q2 25 | 19.0% | -0.6% | ||
| Q1 25 | -1.7% | -2.2% | ||
| Q4 24 | 19.7% | -1.5% | ||
| Q3 24 | 18.1% | -23.4% | ||
| Q2 24 | 19.2% | -0.8% | ||
| Q1 24 | 16.7% | -1.6% |
| Q4 25 | $0.79 | $-0.28 | ||
| Q3 25 | $0.84 | $-0.08 | ||
| Q2 25 | $0.86 | $-0.05 | ||
| Q1 25 | $-0.08 | $-0.18 | ||
| Q4 24 | $0.87 | $-0.17 | ||
| Q3 24 | $0.75 | $-1.81 | ||
| Q2 24 | $0.82 | $-0.06 | ||
| Q1 24 | $0.72 | $-0.13 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $2.4B | $17.0M |
| Total DebtLower is stronger | $2.5B | $387.0M |
| Stockholders' EquityBook value | $5.2B | $1.5B |
| Total Assets | $9.2B | $3.3B |
| Debt / EquityLower = less leverage | 0.48× | 0.25× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $2.4B | $17.0M | ||
| Q3 25 | $2.2B | $25.0M | ||
| Q2 25 | $1.9B | $18.0M | ||
| Q1 25 | $1.6B | $16.0M | ||
| Q4 24 | $2.0B | $35.0M | ||
| Q3 24 | $2.3B | $55.0M | ||
| Q2 24 | $2.4B | $7.0M | ||
| Q1 24 | $2.2B | $7.0M |
| Q4 25 | $2.5B | $387.0M | ||
| Q3 25 | $2.5B | $387.0M | ||
| Q2 25 | $2.5B | $387.0M | ||
| Q1 25 | $2.5B | $387.0M | ||
| Q4 24 | $2.5B | $351.0M | ||
| Q3 24 | $2.5B | $352.0M | ||
| Q2 24 | $2.5B | $370.0M | ||
| Q1 24 | $2.6B | $351.0M |
| Q4 25 | $5.2B | $1.5B | ||
| Q3 25 | $5.0B | $1.6B | ||
| Q2 25 | $4.8B | $1.6B | ||
| Q1 25 | $4.6B | $1.6B | ||
| Q4 24 | $4.8B | $1.6B | ||
| Q3 24 | $5.1B | $1.7B | ||
| Q2 24 | $5.0B | $579.0M | ||
| Q1 24 | $4.8B | $582.0M |
| Q4 25 | $9.2B | $3.3B | ||
| Q3 25 | $9.0B | $3.2B | ||
| Q2 25 | $8.8B | $3.2B | ||
| Q1 25 | $8.5B | $3.3B | ||
| Q4 24 | $8.7B | $3.4B | ||
| Q3 24 | $9.2B | $3.4B | ||
| Q2 24 | $8.9B | $1.8B | ||
| Q1 24 | $8.7B | $1.8B |
| Q4 25 | 0.48× | 0.25× | ||
| Q3 25 | 0.50× | 0.24× | ||
| Q2 25 | 0.52× | 0.24× | ||
| Q1 25 | 0.55× | 0.24× | ||
| Q4 24 | 0.53× | 0.22× | ||
| Q3 24 | 0.49× | 0.21× | ||
| Q2 24 | 0.51× | 0.64× | ||
| Q1 24 | 0.53× | 0.60× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $229.9M | $7.0M |
| Free Cash FlowOCF − Capex | $215.2M | $-9.0M |
| FCF MarginFCF / Revenue | 20.5% | -0.6% |
| Capex IntensityCapex / Revenue | 1.4% | 1.1% |
| Cash ConversionOCF / Net Profit | 1.28× | — |
| TTM Free Cash FlowTrailing 4 quarters | $1.0B | $-8.0M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $229.9M | $7.0M | ||
| Q3 25 | $355.1M | $23.0M | ||
| Q2 25 | $343.3M | $23.0M | ||
| Q1 25 | $169.4M | $-2.0M | ||
| Q4 24 | $189.3M | $-7.0M | ||
| Q3 24 | $367.0M | $-7.0M | ||
| Q2 24 | $405.8M | $-5.0M | ||
| Q1 24 | $292.4M | $7.0M |
| Q4 25 | $215.2M | $-9.0M | ||
| Q3 25 | $341.4M | $9.0M | ||
| Q2 25 | $330.5M | $9.0M | ||
| Q1 25 | $153.9M | $-17.0M | ||
| Q4 24 | $172.5M | $-19.0M | ||
| Q3 24 | $350.6M | $-18.0M | ||
| Q2 24 | $385.3M | $-16.0M | ||
| Q1 24 | $279.6M | $-4.0M |
| Q4 25 | 20.5% | -0.6% | ||
| Q3 25 | 32.5% | 0.6% | ||
| Q2 25 | 32.3% | 0.6% | ||
| Q1 25 | 15.3% | -1.2% | ||
| Q4 24 | 16.9% | -1.1% | ||
| Q3 24 | 35.5% | -1.7% | ||
| Q2 24 | 38.1% | -1.7% | ||
| Q1 24 | 27.5% | -0.4% |
| Q4 25 | 1.4% | 1.1% | ||
| Q3 25 | 1.3% | 1.0% | ||
| Q2 25 | 1.3% | 1.0% | ||
| Q1 25 | 1.5% | 1.0% | ||
| Q4 24 | 1.6% | 0.7% | ||
| Q3 24 | 1.7% | 1.1% | ||
| Q2 24 | 2.0% | 1.2% | ||
| Q1 24 | 1.3% | 1.2% |
| Q4 25 | 1.28× | — | ||
| Q3 25 | 1.90× | — | ||
| Q2 25 | 1.76× | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 0.94× | — | ||
| Q3 24 | 2.05× | — | ||
| Q2 24 | 2.09× | — | ||
| Q1 24 | 1.72× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
HOLX
| Molecular Diagnostics | $255.3M | 24% |
| Breast Imaging | $219.9M | 21% |
| Services | $216.4M | 21% |
| Capital Equipment Componentsand Software | $187.2M | 18% |
| Cytology Perinatal | $76.0M | 7% |
| Interventional Breast Solutions | $71.2M | 7% |
| Blood Screening | $8.4M | 1% |
| Other Typeof Revenue | $5.4M | 1% |
RXO
| Retail Sector | $546.0M | 37% |
| Last Mile | $298.0M | 20% |
| Food And Beverage Sector | $225.0M | 15% |
| Other Sector | $185.0M | 13% |
| Managed Transportation | $133.0M | 9% |
| Automotive Sector | $93.0M | 6% |
